Anavex Life Sciences Corp. filed a Form 8-K with the SEC on August 17, 2026, disclosing under Regulation FD that it had issued a press release and mailed a letter to stockholders in connection with its 2026 Annual Meeting of Stockholders.

Key Highlights

  • Filing date: August 17, 2026, under Item 7.01 (Regulation FD Disclosure)
  • Disclosure: Anavex announced the mailing of a letter to stockholders regarding its 2026 Annual Meeting of Stockholders
  • Exhibits: A press release (Exhibit 99.1) and a Stockholder Letter (Exhibit 99.2), both dated August 17, 2026, were furnished with the filing
  • Not "filed": The information in Item 7.01 is expressly stated as not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934
  • Signed by: Sandra Boenisch, CPA, CGA, Principal Financial Officer and Treasurer of Anavex Life Sciences Corp.

Anavex Mails Annual Meeting Letter to Stockholders, Furnishes Related Materials

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company listed on NASDAQ:AVXL with common stock having a par value of $0.001 per share, disclosed on August 17, 2026, that it had issued communications to stockholders ahead of its 2026 Annual Meeting of Stockholders. According to the filing, the company issued a press release announcing the mailing of a stockholder letter related to the Annual Meeting, with both the press release and the letter furnished as exhibits to the Current Report.

The filing was made under Item 7.01, covering Regulation FD disclosures, and the company noted that the information furnished, including Exhibits 99.1 and 99.2, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended." The filing further stated that the furnished materials are not deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. The company's principal offices are located at 630 5th Avenue, 20th Floor, New York, NY 10111, and the filing was signed by Principal Financial Officer Sandra Boenisch, CPA, CGA.

What Was Disclosed

Anavex Life Sciences Corp. furnished an 8-K on August 17, 2026, disclosing the mailing of a stockholder letter and issuance of a press release tied to its 2026 Annual Meeting of Stockholders, with both documents attached as exhibits to the report.